Fortunately, as never before, advances in medication and treatment are enabling men and women to lessen the symptoms of COPD, retain greater lung function, and maintain full, active, and independent lives.
Evidence suggests that higher levels of vitamin D and calcium are associated with greater lung function and that vitamin D is inversely associated with atopic sensitisation.
Measurement of lung function (ie, FVC and DLCO) and exercise tolerance tends to be difficult in patients with greater lung function impairment, and the incidence of acute exacerbation could be low in patients with lesser lung function impairment.
More specifically, it was hypothesised that lower sedentary behaviour and higher levels of physical activity would be related to greater exercise capacity, greater lung function, better HRQoL and higher self-efficacy, perceiving more benefits of physical activity and using more processes of change.
We hypothesised that lower levels of sedentary behaviour and higher levels of physical activity would be related to greater exercise capacity, greater lung function, better HRQoL and higher self-efficacy, perceiving more benefits of physical activity and using more processes of change.
Combining bronchodilators with complementary modes of action in COPD offers greater lung function benefits than individual agents, with similar tolerability and safety [ 2, 3].
Airway neutrophils, eosinophils, and T and B lymphocytes during infection are related to virus load and physiologic and clinical severity, whereas mast cells are related to greater lung function.
However, in contrast to the significantly greater lung function improvements seen with UMEC/VI versus FP/SAL, no treatment differences were seen for these endpoints.
In this study, it was observed that patients using higher-dose ICS at baseline showed a comparatively greater lung function benefit with FF 200 μg than with FF 100 μg.
Patients with urinary GAG excretion greater than 200 ug/mg creatinine had more severe disease characterized by short stature, low weight, greater difficulty in performing the 6-minute walk test, greater impairment of lung function, and joint restriction.
Combination therapy with FP plus salmeterol (SFC) produced significantly greater improvements in lung function and asthma control than the addition of montelukast to FP.
